Comparative Pharmacology
Head-to-head clinical analysis: INFLAMASE FORTE versus PREDAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFLAMASE FORTE versus PREDAMIDE.
INFLAMASE FORTE vs PREDAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Predamide (a combination of prednisolone and sulfadimethoxine) exerts its effects via the corticosteroid anti-inflammatory action of prednisolone (inhibition of phospholipase A2, reduced prostaglandin synthesis) and the bacteriostatic action of sulfadimethoxine (competitive antagonism of para-aminobenzoic acid, inhibiting dihydropteroate synthase in folate synthesis).
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
Prednisone 5 mg orally once daily, adjusted based on response.
None Documented
None Documented
Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life: 12-15 hours. In hepatic impairment, half-life may extend to 20-25 hours; in renal impairment (CrCl <30 mL/min), half-life increases to 30-40 hours.
Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination.
Renal (80% as unchanged drug and metabolites, primarily glucuronide and sulfate conjugates), biliary/fecal (20%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Sulfonamide Combination